Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study

Table 1 Multivariate analysis of MTX failure

Variable	Multivariate Cox analysis^a		Multivariate competing risks analysis^b
	Reason for MTX failure		Reason for MTX failure
	Adverse event (N = 67)	Inefficacy (N = 143)	Adverse event (N = 67)	Inefficacy (N = 143)
Age of disease onset	NR	0.97 (0.96, 0.99) p < 0.001	NR	0.97 (0.96, 0.99) p < 0.001
Female gender	1.39 (0.82, 2.35) p = 0.221	1.34 (0.90, 1.99) p = 0.143	1.28 (0.78, 2.14) p = 0.325	1.23 (0.83, 1.40) p = 0.298
BMI	NR	1.02 (0.99, 1.05) p = 0.182	NR	1.02 (0.99, 1.05) p = 0.184
Current smoker	NR	1.41 (0.86, 2.32) p = 0.176	NR	1.43 (0.88, 2.36) p = 0.150
Symptom duration	NR	1.00 (1.00, 1.00) p = 0.174	NR	1.00 (1.00, 1.00) p = 0.120
HAQ score at baseline	1.39 (0.98, 1.96) p = 0.064	1.15 (0.88, 1.49) p = 0.314	1.34 (0.96, 1.86) p = 0.092	1.07 (0.82, 1.40) p = 0.606
DAS-28(CRP) at baseline	NR	1.27 (1.10, 1.47) p = 0.001	NR	1.23 (1.05, 1.43) p = 0.008
Shared epitope homozygosity	NR	1.44 (0.81, 2.58) p = 0.214	NR	1.42 (0.79, 2.56) p = 0.235
Rheumatoid factor positivity	0.37 (0.21, 0.64) p < 0.001	1.44 (0.98, 2.13) p = 0.064	0.34 (0.20, 0.59) p < 0.001	1.67 (1.13, 2.48) p = 0.011
ACPA positivity^c	NR	NR	NR	NR

NR not reported, BMI body mass index, HAQ, Health Assessment Questionnaire, DAS-28(CRP) disease activity score-28-C-reactive protein, ACPA anti-citrullinated protein antibody
^aValues are HR (95% CI)
^bValues are exponentiated coefficients (exp(beta); subdistribution hazard ratio (sHR)). (95% CI)
^cIncluded in univariate model only. Bold values represent P < 0.05

ISSN: 1478-6362